Market Access Insights
Access the relevant market access data and insights you need on health plans, policy restrictions, PBMs, providers, and more
Getting Ahead of the Reimbursement Curve: How Will Your Immune Biologic Brand Fare?
Thanks to healthcare reform, prodding by the federal government and new benefit designs, we’re seeing substantial changes in store with the market.With the rollout of new Medicare plans for 2011, we’r…
Formulary Advantages in Immune Biologics: Brand Maneuvering in a Market Increasingly Constrained by Limited Payer Reimbursement
Immune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis and ankylosing spondylitis produce a substantial amount of human suffering and disability. Biol…